PET Used Instead of Repeated Biopsy for Monitoring of Prostate Cancer
By MedImaging International staff writers Posted on 30 Apr 2014 |
A study described a method to direct the lipid metabolism in cancer cells to use more of radiolabeled glucose.
Most tumors are fed by metabolizing glucose, and therefore can be seen in positron emission tomography (PET) imaging scans that detect radiolabeled glucose. However, prostate cancers tend to use the lipid metabolism pathway and so cannot very effectively be imaged in this way.
A University of Colorado (CU) Cancer Center (Aurora, USA) study presented at the American Association for Cancer Research (AACR) annual meeting held April 5–9, 2014, in San Diego (CA, USA) described an innovative way to “manipulate the lipid metabolism in the cancer cell to trick them to use more radiolabeled glucose, the basis of PET scanning.” The statement was made by Isabel Schlaepfer, PhD, an investigator at the CU Cancer Center department of pharmacology, and recipient of a 2014 Minority Scholar Award in Cancer Research from AACR.
The current study used the clinically safe pharmaceutical agent etomoxir to cut off prostate cancer cells’ ability to oxidize lipids. With the lipid energy source removed, cells switched to glucose metabolism and both cells and mouse models roughly doubled their uptake of radiolabeled glucose. “Because prostate cancer can be a slow-growing disease, instead of immediate treatment, many men choose active surveillance—they watch and wait. But that requires repeated prostate biopsies. Instead, now we could use this metabolic technique to allow PET imaging to monitor prostate cancer progression without the need for so many biopsies,” said Dr. Schlaepfer.
Furthermore, Dr. Schlaepfer pointed out possible therapeutic application of the technique: while immediately useful for imaging, it may be that blocking a prostate cancer cell’s ability to supply itself with energy from lipids could make it difficult for these cells to survive.
The University of Colorado Cancer Center is currently recruiting participants for a human clinical trial of the fat-burning inhibitor ranolazine to enhance PET imaging during the active monitoring of prostate cancer (NCT01992016).
Related Links:
University of Colorado Cancer Center
Most tumors are fed by metabolizing glucose, and therefore can be seen in positron emission tomography (PET) imaging scans that detect radiolabeled glucose. However, prostate cancers tend to use the lipid metabolism pathway and so cannot very effectively be imaged in this way.
A University of Colorado (CU) Cancer Center (Aurora, USA) study presented at the American Association for Cancer Research (AACR) annual meeting held April 5–9, 2014, in San Diego (CA, USA) described an innovative way to “manipulate the lipid metabolism in the cancer cell to trick them to use more radiolabeled glucose, the basis of PET scanning.” The statement was made by Isabel Schlaepfer, PhD, an investigator at the CU Cancer Center department of pharmacology, and recipient of a 2014 Minority Scholar Award in Cancer Research from AACR.
The current study used the clinically safe pharmaceutical agent etomoxir to cut off prostate cancer cells’ ability to oxidize lipids. With the lipid energy source removed, cells switched to glucose metabolism and both cells and mouse models roughly doubled their uptake of radiolabeled glucose. “Because prostate cancer can be a slow-growing disease, instead of immediate treatment, many men choose active surveillance—they watch and wait. But that requires repeated prostate biopsies. Instead, now we could use this metabolic technique to allow PET imaging to monitor prostate cancer progression without the need for so many biopsies,” said Dr. Schlaepfer.
Furthermore, Dr. Schlaepfer pointed out possible therapeutic application of the technique: while immediately useful for imaging, it may be that blocking a prostate cancer cell’s ability to supply itself with energy from lipids could make it difficult for these cells to survive.
The University of Colorado Cancer Center is currently recruiting participants for a human clinical trial of the fat-burning inhibitor ranolazine to enhance PET imaging during the active monitoring of prostate cancer (NCT01992016).
Related Links:
University of Colorado Cancer Center
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment